King’s College London ALS Researcher Honored with $50,000 Sheila Essey Award at AAN Annual Meeting
The ALS Association and the American Academy of Neurology (AAN) have chosen Professor Ammar Al-Chalabi of King’s College London to receive…
Articles by Margarida Azevedo, MSc
Molecular Stethoscope Working to Validate a Diagnostic Test for ALS and Other Diseases
Molecular Stethoscope, Inc., announced it is working with 23 U.S. academic and medical institutions to further validate its blood-based early diagnostic and disease…
Mobile Laptop System Helps ALS Patients and Others with Limited Mobility Communicate by Eye Movement
Researchers created a mobile cart device allowing people to communicate via laptops by eye movement alone. The device was designed with severely disabled…
Predictive Model of ALS Progression Being Tested with Support of ALS Association
Origent Data Sciences, Inc., and Cytokinetics, Inc., announced a new research partnership to further refine and validate an Origent computer model…
AB Science Reports Positive Interim Results in Phase 3 Trial of Masitinib as an ALS Therapy
AB Science announced that its Phase 2/3 clinical trial evaluating masitinib, the company’s lead compound to treat amyotrophic lateral sclerosis (ALS)…
Neuraltus Pharmaceuticals Readies Second Phase 2 Study of Potential ALS Therapy
Neuraltus Pharmaceuticals announced that it will initiate a second Phase 2 clinical trial of its investigational drug candidate NP001 for the treatment…
Stem Cell Technology Leaders Review ALS Therapies, Promote Collaboration
Leaders in the field of induced pluripotent stem cell (iPSC) – a technology that can help derive motor neurons from people…
US Cities to Get Expert-led ‘ALS Unfiltered’ Series, Promoted by ALS.net
ALS.net has just announced the launch of “ALS Unfiltered,” a series of public sessions that will offer expert-led presentations…
UC Researchers Awarded $6.3M to Explore an ALS Stem Cell Therapy Based on Astrocytes
The California Institute for Regenerative Medicine (CIRM)’s Independent Citizens Oversight Committee has approved a $6.3 million grant to fund a research…
Eisai Withdraws Application for Ultra-High Dose of Mecobalamin, a B12 Form, as ALS Treatment
Eisai announced it has withdrawn its new drug application for an ultra-high dose Mecobalamin as a treatment for amyotrophic lateral…